SLRC Stock Analysis: SLR Investment | NASDAQ
Asset Management | NASDAQ, USA | Market Cap: 674m USD | 12M Return: -13.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.95M
EPS Trend: -42.4%
Qual. Beats: -1
Rev. Trend: 54.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
SLR Investment Corp. is a Business Development Company (BDC) that provides debt and equity financing to leveraged middle-market companies. Its investment offerings include first-lien and second-lien secured loans, subordinated unsecured debt, and minority equity stakes, supporting leveraged buyouts, acquisitions, recapitalizations, refinancings, and growth capital transactions.
The fund maintains an exceptionally broad sector mandate, spanning roughly 50+ industries including aerospace and defense, healthcare, software, financial services, manufacturing, retail, telecommunications, energy, and consumer products. Within healthcare, it specifically targets life sciences sub-sectors such as specialty pharmaceuticals, medical devices, and biotechnology.
As a BDC, SLR Investment Corp. operates under a regulated structure that requires it to distribute most of its taxable income to shareholders, making it part of the financials sector with a focus on asset management and custody banking activities.
- Fed rate cuts compress net interest margin
- Non-accruals rise on middle market credit stress
- Net investment income fails to cover dividend distribution
| Net Income: 89.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.04 > 0.02 and ΔFCF/TA -18.39 > 1.0 |
| NWC/Revenue: 85.40% < 20% (prev 26.66%; Δ 58.73% < -1%) |
| CFO/TA -0.04 > 3% & CFO -91.6m > Net Income 89.7m |
| Net Debt (1.13b) to EBITDA (109.3m): 10.32 < 3 |
| Current Ratio: 1.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (54.6m) vs 12m ago -0.00% < -2% |
| Gross Margin: 63.99% > 18% (prev 58.40%; Δ 5.59% > 0.5%) |
| Asset Turnover: 7.24% > 50% (prev 6.64%; Δ 0.60% > 0%) |
| Interest Coverage Ratio: 1.55 > 6 (EBIT TTM 106.1m / Interest Expense TTM 68.4m) |
| A: 0.06 (Total Current Assets 425.8m - Total Current Liabilities 269.9m) / Total Assets 2.54b |
| B: -0.05 (Retained Earnings -124.8m / Total Assets 2.54b) |
| C: 0.04 (EBIT TTM 106.1m / Avg Total Assets 2.52b) |
| D: 0.64 (Book Value of Equity 990.8m / Total Liabilities 1.55b) |
| Altman-Z'' = 1.20 = BB |
As of July 08, 2026, the stock is trading at USD 12.60 with a total of 335,960 shares traded. Over the past week, the price has changed by +1.04%, over one month by +1.33%, over three months by -11.88% and over the past year by -13.67%.
Current recommended Stop Loss: 12.10 (which is 4% or 1.8 ATR below the current price).
SLR Investment has received a consensus analysts rating of 3.56. Therefore, it is recommended to hold SLRC.
- StrongBuy: 3
- Buy: 2
- Hold: 2
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 15.6 | 23.5% |
P/E Trailing = 7.5366
P/E Forward = 8.5543
P/S = 3.1413
P/B = 0.6855
P/EG = 4.3701
Revenue TTM = 182.5m USD
EBIT TTM = 106.1m USD
EBITDA TTM = 109.3m USD
Long Term Debt = 868.3m USD (estimated: total debt 1.14b - short term 269.9m)
Short Term Debt = 269.9m USD (from shortTermDebt, last quarter)
Debt = 1.14b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.13b USD (calculated: Debt 1.14b - CCE 11.2m)
Enterprise Value = 1.80b USD (674.3m + Debt 1.14b - CCE 11.2m)
Interest Coverage Ratio = 1.55 (Ebit TTM 106.1m / Interest Expense TTM 68.4m)
EV/FCF = -19.66x (Enterprise Value 1.80b / FCF TTM -91.6m)
FCF Yield = -5.09% (FCF TTM -91.6m / Enterprise Value 1.80b)
FCF Margin = -50.20% (FCF TTM -91.6m / Revenue TTM 182.5m)
Net Margin = 49.16% (Net Income TTM 89.7m / Revenue TTM 182.5m)
Gross Margin = 63.99% ((Revenue TTM 182.5m - Cost of Revenue TTM 65.7m) / Revenue TTM)
Gross Margin QoQ = 72.25% (prev 62.69%)
Tobins Q-Ratio = 0.71 (Enterprise Value 1.80b / Total Assets 2.54b)
Interest Expense / Debt = 6.01% (Interest Expense 68.4m / Debt 1.14b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 83.8m (EBIT 106.1m * (1 - 21.00%))
Current Ratio = 1.58 (Total Current Assets 425.8m / Total Current Liabilities 269.9m)
Debt / Equity = 1.15 (Debt 1.14b / totalStockholderEquity, last quarter 990.8m)
Debt / EBITDA = 10.32 (Net Debt 1.13b / EBITDA 109.3m)
Debt / FCF = -12.30 (negative FCF - burning cash) (Net Debt 1.13b / FCF TTM -91.6m)
Total Stockholder Equity = 993.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.56% (Net Income 89.7m / Total Assets 2.54b)
RoE = 9.04% (Net Income TTM 89.7m / Total Stockholder Equity 993.1m)
RoCE = 5.70% (EBIT 106.1m / Capital Employed (Equity 993.1m + L.T.Debt 868.3m))
RoIC = 3.31% (NOPAT 83.8m / Invested Capital 2.53b)
WACC = 5.81% (E(674.3m)/V(1.81b) * Re(7.61%) + D(1.14b)/V(1.81b) * Rd(6.01%) * (1-Tc(0.21)))
Discount Rate = 7.61% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -3.11 | Cagr: 0.0%
[DCF] Fair Price = unknown (Cash Flow -91.6m)
EPS Correlation: -42.44 | EPS CAGR: -2.10% | SUE: -4.0 | # QB: -1
Revenue Correlation: 54.02 | Revenue CAGR: 6.35% | SUE: -0.27 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.33 | Chg30d=-15.66% | Revisions=-70% | Analysts=7
EPS next Quarter (2026-09-30): EPS=0.33 | Chg30d=-15.79% | Revisions=-70% | Analysts=7
EPS current Year (2026-12-31): EPS=1.32 | Chg30d=-15.99% | Revisions=-73% | GrowthEPS=-16.8% | GrowthRev=-10.1%
EPS next Year (2027-12-31): EPS=1.36 | Chg30d=-9.97% | Revisions=-67% | GrowthEPS=+2.9% | GrowthRev=+1.8%
[Analyst] Revisions Ratio: -90% (up=0, down=28)